Effect of omalizumab on angioedema in H 1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ ACT , a randomized controlled trial
Allergy2016Vol. 71(8), pp. 1135–1144
Citations Over TimeTop 1% of 2016 papers
Petra Staubach, Martin Metz, Nadine Chapman‐Rothe, Christian Sieder, Matthias Bräutigam, Janice Canvin, Marcus Maurer
Abstract
Omalizumab was an effective treatment option for patients with moderate-to-severe CSU symptoms and angioedema unresponsive to high doses of antihistamine treatment.
Related Papers
- → Effect of omalizumab on angioedema in H 1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ ACT , a randomized controlled trial(2016)128 cited
- → Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab(2019)3 cited
- → Efficacy of Omalizumab for the Treatment of Allergic Urticaria and Angioedema(2007)2 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)
- → Private Practice Experience with Omalizumab for Chronic Urticaria(2020)